Saudi Chemical Company Holding Announces Signing a Collaboration Agreement with GlaxoSmithKline Consumer Healthcare Saudi Limited for Manufacturing in Saudi Arabia.
|Announcement Detail||Riyadh, Saudi Arabia – June 3, 2021 - Saudi Chemical Company Holding (SCCH), through its pharmaceutical sector represented by AJA Pharmaceutical Industries Ltd. (AJA Pharma), signed a contractual agreement with GlaxoSmithKline Consumer Healthcare Saudi Limited on manufacturing in AJA Pharma manufacturing site in Saudi Arabia. |
This agreement aims to benefit from GlaxoSmithKline Consumer Healthcare experiences in the consumer health care sector and ensure the transfer of technology for the Consumer Healthcare products to the Kingdom of Saudi Arabia, followed by the commercial-scale production in AJA Pharma manufacturing site. The contractual agreement is for 5 years with an expected revenue of around SAR 100 Mn, driving an increase the production capacity, and thereby expected to result in creating more employment opportunities for Saudis.
Commenting on the agreement, Eng. Thamer Al-Muhid, Group Chief Executive Officer of (SCCH), said that this strategic collaboration would contribute to localisation's national objective. He further emphasised that AJA Pharma aims to provide high-quality pharmaceutical products for the Global Pharma companies operating in the region. “Our mission is to be the partner of choice!” said the GCEO.
About AJA Pharma: AJA Pharmaceutical Industries Company Limited is a subsidiary of Saudi Chemical Company Holding. The Holding company is listed in the Saudi Stock Exchange, Tadawul. AJA Pharma has a Pharmaceutical Manufacturing site in Ha’il, Saudi Arabia.
About GSK : GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.